Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 14.69
NAS:ATHX's Cash-to-Debt is ranked lower than
55% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:ATHX: 14.69 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ATHX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 166.3 Max: No Debt
Current: 14.69
Equity-to-Asset 0.59
NAS:ATHX's Equity-to-Asset is ranked lower than
60% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ATHX: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ATHX' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.69  Med: 0.67 Max: 1
Current: 0.59
-4.69
1
Interest Coverage N/A
NAS:ATHX's Interest Coverage is ranked lower than
57% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ATHX: N/A )
Ranked among companies with meaningful Interest Coverage only.
NAS:ATHX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: -10.24
Beneish M-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -86.62
NAS:ATHX's Operating Margin % is ranked higher than
51% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:ATHX: -86.62 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ATHX' s Operating Margin % Range Over the Past 10 Years
Min: -1787.55  Med: -399.32 Max: -86.62
Current: -86.62
-1787.55
-86.62
Net Margin % -88.41
NAS:ATHX's Net Margin % is ranked lower than
51% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:ATHX: -88.41 )
Ranked among companies with meaningful Net Margin % only.
NAS:ATHX' s Net Margin % Range Over the Past 10 Years
Min: -1360.57  Med: -374.33 Max: -88.41
Current: -88.41
-1360.57
-88.41
ROE % -83.23
NAS:ATHX's ROE % is ranked lower than
75% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:ATHX: -83.23 )
Ranked among companies with meaningful ROE % only.
NAS:ATHX' s ROE % Range Over the Past 10 Years
Min: -176.55  Med: -103.12 Max: -45.44
Current: -83.23
-176.55
-45.44
ROA % -59.73
NAS:ATHX's ROA % is ranked lower than
73% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:ATHX: -59.73 )
Ranked among companies with meaningful ROA % only.
NAS:ATHX' s ROA % Range Over the Past 10 Years
Min: -99.51  Med: -67.53 Max: -41.79
Current: -59.73
-99.51
-41.79
ROC (Joel Greenblatt) % -781.14
NAS:ATHX's ROC (Joel Greenblatt) % is ranked lower than
59% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:ATHX: -781.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ATHX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4646.21  Med: -1644.96 Max: -781.14
Current: -781.14
-4646.21
-781.14
3-Year Revenue Growth Rate 69.60
NAS:ATHX's 3-Year Revenue Growth Rate is ranked higher than
91% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:ATHX: 69.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ATHX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -18.6 Max: 69.6
Current: 69.6
0
69.6
3-Year EBITDA Growth Rate -25.50
NAS:ATHX's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:ATHX: -25.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ATHX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -25.5 Max: -10.7
Current: -25.5
3-Year EPS without NRI Growth Rate -30.20
NAS:ATHX's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:ATHX: -30.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ATHX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.2 Max: -4.1
Current: -30.2
GuruFocus has detected 3 Warning Signs with Athersys Inc $NAS:ATHX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ATHX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ATHX Guru Trades in Q1 2016

Jim Simons 343,034 sh (+204.02%)
» More
Q2 2016

ATHX Guru Trades in Q2 2016

Joel Greenblatt 10,296 sh (New)
Jim Simons 246,534 sh (-28.13%)
» More
Q3 2016

ATHX Guru Trades in Q3 2016

Joel Greenblatt Sold Out
Jim Simons 136,834 sh (-44.50%)
» More
Q4 2016

ATHX Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:INFI, NAS:VTL, AMEX:AST, NAS:REPH, NAS:KIN, NAS:SBBP, NAS:CBMG, AMEX:PLX, NAS:ALBO, NAS:CNAT, NAS:IMDZ, NAS:GNCA, OTCPK:ATVBF, AMEX:OCX, OTCPK:PHGUF, NAS:VBLT, NAS:QURE, NAS:MDWD, NAS:NYMX, NAS:ABUS » details
Traded in other countries:4LS.Germany,
Headquarter Location:USA
Athersys Inc is a biopharmaceutical company developing regenerative medicine. It is engaged in the discovery and development of therapies designed to extend and enhance human life.

Development-stage biotech Athersys is developing therapies for the treatment of serious diseases. Its flagship biologic product MultiStem is manufactured from human stem cells obtained from adult bone marrow and is undergoing testing for heart attack, bone marrow transplant support, stroke, and other conditions. Outside of its stem cell technology, Athersys is also developing several small-molecule candidates for the treatment of obesity and certain neurological conditions.

Top Ranked Articles about Athersys Inc

Athersys to Host First Quarter Financial Results Call
Athersys to Present at Needham Healthcare Conference on April 4

CLEVELAND, March 29, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the 16th Annual Needham Healthcare Conference at The Westin New York Grand Central Hotel in New York City.  The presentation is scheduled for Tuesday, April 4, 2017 at 12:10 pm ET.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.athersys.com. An archived replay of the webcast will be available for 90 days on the Company's website after the conference. About Athersys Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys. ATHX-G
Contact:

William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
[email protected]

David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
[email protected]

Investor Contact:
Peter Vozzo
Westwicke Partners
(443) 213-0505 or (443) 377-4767 (mobile)
[email protected]

Read more...
Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke

Lancet Neurology/Stem Cells publications provide further clarity of MultiStem mechanisms of benefit – modulating inflammatory response and immune system – enhancing recovery

CLEVELAND, March 20, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that clinical investigators have published results from Athersys’ Phase 2 trial of MultiStem cell therapy for treating ischemic stroke patients (the “MASTERS” trial) in the peer-reviewed journal, The Lancet Neurology.  The article highlights the feasibility and safety of intravenous MultiStem treatment for patients who have suffered a moderate to severe stroke, the progressive improvements in recovery experienced by these patients through one year, and the increased benefit for those patients receiving MultiStem treatment within 36 hours of their stroke.  In addition, the article describes how patients receiving intravenous MultiStem treatment demonstrated a significant reduction in inflammatory cytokines and immune cells and a decrease in infections associated with immunodepression, compared to patients receiving placebo. These trial findings, together with the article below, provide further clarity about important mechanisms of benefit when treating stroke patients with MultiStem – the modulation of the inflammatory response and preservation of immune system homeostasis – promoting accelerated recovery. “As described in the clinical paper, there were several important observations from the MASTERS study, including evidence that intravenous administration of MultiStem was associated with a substantial increase in the proportion of stroke victims who achieved an Excellent Outcome (defined below) at one year, particularly when treatment occurred within 36 hours of the ischemic event,” commented Dr. David Hess, stroke specialist and Professor & Chairman of the Department of Neurology at the Medical College of Georgia at Augusta University, primary author of the article and lead clinical investigator in the MASTERS trial. “The combination of these observations in conjunction with the clinical safety data and supportive biomarker data from the trial provide a clear basis for moving forward in the MASTERS-2 study.” This publication coincides with another independent article highlighting additional evidence from preclinical studies of how MultiStem cell therapy provides multiple biological benefits following an ischemic stroke, including data supporting key mechanisms of action. The preclinical research, published in the journal, Stem Cells, demonstrates that following a stroke, administration of the cell therapy modulates the inflammatory response initiated by the stroke injury, by down-regulating inflammatory cytokines and immune cells that cause extensive damage in the brain following a stroke or other neurological injury. The publication describes how MultiStem cells minimize this acute inflammatory response by interacting with peripheral immune organs, most notably the spleen. By inhibiting the body’s inflammatory response to the stroke injury and stimulating key reparative mechanisms, MultiStem treatment results in less damage in the brain and promotes more effective recovery. “A strong foundation of data has been established that illustrates the importance of the spleen and peripheral immune system following an acute neurological injury such as a stroke,” commented Dr. Sean Savitz, Professor of Neurology and Chair of the Department of Neurology at University of Texas, Health Science Center at Houston and McGovern Medical School.  “Our preclinical work demonstrates that administration of MultiStem cell therapy has a profound effect on neutralizing the inflammatory-mediated damage that occurs acutely following an ischemic stroke, as well as upregulating reparative pathways, which is consistent with the biomarker data from the MASTERS trial,”  concluded Dr. Savitz. Athersys is planning a Phase 3 study entitled, MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (“MASTERS-2”).  The MASTERS-2 study has received authorization from the U.S. Food and Drug Administration (“FDA”) under a Special Protocol Assessment (“SPA”) for the design and planned analysis of the pivotal Phase 3 clinical trial.  The SPA provides formal agreement from the FDA that the protocol design, clinical endpoints, planned conduct and statistical analyses in the Phase 3 study are acceptable to support a regulatory submission for marketing approval of MultiStem cell therapy as a product for treating ischemic stroke patients, if the trial is successful. Additionally, the Ministry of Health Labor and Welfare recently provided public notification that the TREASURE Phase 2/3 stroke study being conducted in Japan by Athersys’ partner, HEALIOS K.K., has received a priority review designation, enabling acceleration of the potential assessment time to six months for Japan’s Pharmaceutical and Medical Devices Agency review (under the recently implemented accelerated review pathway for innovative medicines, or Sakigake). The MASTERS-2 clinical trial is a randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to enroll 300 patients at stroke clinical centers in North America and Europe. These patients will have suffered a moderate to severe stroke and will receive either a single intravenous dose of MultiStem cell therapy or placebo, administered within 18-36 hours of the occurrence of the stroke, in addition to the standard of care. The primary endpoint will evaluate disability using modified Rankin Scale (“mRS”) scores at three months, comparing the distribution, or the “shift”, between the MultiStem treatment and placebo groups. The mRS shift analysis considers disability across the full spectrum, enabling recognition of large and small improvements in disability and differences in mortality and other serious outcomes, among strokes of different severities. The study will also assess the defined Excellent Outcome (mRS ≤1, NIHSS ≤1, and Barthel Index ≥95) at three months and one year as key secondary endpoints.  Additionally, the study will consider other measures of functional recovery, biomarker data and clinical outcomes, including hospitalization, mortality and life-threatening adverse events and post-stroke complications such as infection. About Ischemic Stroke 
Stroke represents an area where the clinical need is particularly significant, since it is a leading cause of death and serious disability worldwide, with a substantially impaired quality of life for many stroke victims. Currently, there are nearly 17 million people who suffer a stroke globally and more than 2 million stroke victims each year in the United States, Europe and Japan, combined. Ischemic strokes, which represent the most common form of stroke, are caused by a blockage of blood flow in the brain that cuts off the supply of oxygen and nutrients and can result in long-term or permanent disability due to neurological damage. Unfortunately, current therapeutic options for ischemic stroke victims are limited because the only available therapies, administration of the clot dissolving agent tPA, or “thrombolytic,” or surgical intervention using mechanical reperfusion to remove the clot, must be conducted within several hours of the occurrence of the stroke. As a consequence of this limited time window, only a small percentage of stroke victims are treated with the currently available therapy—most simply receive supportive or “palliative” care. The long-term costs of stroke are substantial, with many patients requiring extended hospitalization, extensive physical therapy or rehabilitation (for those patients that are capable of entering such programs), and many require long-term institutional or family care. About MultiStem
MultiStem cell therapy is a patented regenerative medicine product that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage.  MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The product represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent safety profile demonstrated in both preclinical and clinical settings, MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need. Athersys has forged strategic partnerships and a broad network of collaborations to develop MultiStem cell therapy for a variety of indications, with an initial focus in the neurological, cardiovascular and inflammatory and immune disorder areas. About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.  Follow Athersys on Twitter at www.twitter.com/athersys. Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," “suggest,” "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as therapeutics, such as the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: the establishment of a license agreement with an animal healthcare company, including our ability to reach milestones and receive milestone payments, and whether any products are successfully developed and sold so that we earn royalty payments under any such license agreement; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our collaborators' ability to continue to fulfill their obligations under the terms of our collaboration agreements; the success of our efforts to enter into new strategic partnerships or collaborations and advance our programs; our ability to raise additional capital; the possibility of delays in, adverse results of, and excessive costs of the development process; changes in external market factors; changes in our industry's overall performance; our ability to protect our intellectual property portfolio; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. ATHX-STR
Contact:

William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
[email protected]

David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
[email protected]

Investor Contact:
Peter Vozzo
Westwicke Partners
(443) 213-0505 or (443) 377-4767 (mobile)
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 11.63
ATHX's PB Ratio is ranked lower than
89% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ATHX: 11.63 )
Ranked among companies with meaningful PB Ratio only.
ATHX' s PB Ratio Range Over the Past 10 Years
Min: 0.18  Med: 4.82 Max: 23.38
Current: 11.63
0.18
23.38
PS Ratio 7.24
ATHX's PS Ratio is ranked higher than
59% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ATHX: 7.24 )
Ranked among companies with meaningful PS Ratio only.
ATHX' s PS Ratio Range Over the Past 10 Years
Min: 1.15  Med: 7.59 Max: 152.38
Current: 7.24
1.15
152.38
EV-to-EBIT -11.84
ATHX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ATHX: -11.84 )
Ranked among companies with meaningful EV-to-EBIT only.
ATHX' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.3  Med: -2.7 Max: 3
Current: -11.84
-53.3
3
EV-to-EBITDA -12.14
ATHX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ATHX: -12.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATHX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.6  Med: -2.7 Max: 3.1
Current: -12.14
-57.6
3.1
Current Ratio 2.37
ATHX's Current Ratio is ranked lower than
69% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ATHX: 2.37 )
Ranked among companies with meaningful Current Ratio only.
ATHX' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 5.01 Max: 12.58
Current: 2.37
0.47
12.58
Quick Ratio 2.37
ATHX's Quick Ratio is ranked lower than
65% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ATHX: 2.37 )
Ranked among companies with meaningful Quick Ratio only.
ATHX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 5.01 Max: 12.58
Current: 2.37
0.47
12.58
Days Sales Outstanding 12.58
ATHX's Days Sales Outstanding is ranked higher than
87% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ATHX: 12.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATHX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.03  Med: 45.04 Max: 156.08
Current: 12.58
11.03
156.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.00
ATHX's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ATHX: -7.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATHX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -298.1  Med: -41 Max: 0
Current: -7
-298.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 18.75
ATHX's Price-to-Net-Cash is ranked lower than
81% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ATHX: 18.75 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATHX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.33  Med: 6.57 Max: 19.13
Current: 18.75
0.33
19.13
Price-to-Net-Current-Asset-Value 15.00
ATHX's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ATHX: 15.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATHX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.32  Med: 6.09 Max: 15.3
Current: 15
0.32
15.3
Price-to-Tangible-Book 11.54
ATHX's Price-to-Tangible-Book is ranked lower than
84% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ATHX: 11.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATHX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.27  Med: 4.78 Max: 11.86
Current: 11.54
0.27
11.86
Price-to-Median-PS-Value 0.96
ATHX's Price-to-Median-PS-Value is ranked lower than
56% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ATHX: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATHX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.82 Max: 9.88
Current: 0.96
0.2
9.88
Earnings Yield (Greenblatt) % -8.45
ATHX's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ATHX: -8.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATHX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.7  Med: 206.2 Max: 17247.5
Current: -8.45
-8.7
17247.5

More Statistics

Revenue (TTM) (Mil) $17.35
EPS (TTM) $ -0.17
Beta-0.38
Short Percentage of Float3.99%
52-Week Range $1.02 - 2.60
Shares Outstanding (Mil)109.80

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 159
EPS ($) -0.30 -0.19 0.58
EPS without NRI ($) -0.30 -0.19 0.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATHX

Headlines

Articles On GuruFocus.com
Athersys to Host First Quarter Financial Results Call Apr 10 2017 
Athersys to Present at Needham Healthcare Conference on April 4 Mar 29 2017 
Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke Mar 20 2017 
Athersys Inc. (ATHX) CEO Bokkelen Gil Van buys 10,000 Shares Mar 18 2009 

More From Other Websites
Athersys to Host First Quarter Financial Results Call Apr 10 2017
Can the Rally in Athersys (ATHX) Shares Continue? Mar 31 2017
Here's What Might Be Pushing Up Shares of Athersys, Inc. Today Mar 31 2017
Tonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward Mar 30 2017
Is the Options Market Predicting a Spike in Athersys (ATHX) Stock? Mar 30 2017
Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage Mar 29 2017
Athersys to Present at Needham Healthcare Conference on April 4 Mar 29 2017
ETFs with exposure to Athersys, Inc. : March 27, 2017 Mar 27 2017
Athersys, Inc. :ATHX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke Mar 20 2017
Athersys, Inc. :ATHX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Edited Transcript of ATHX earnings conference call or presentation 9-Mar-17 9:30pm GMT Mar 09 2017
Athersys Reports Financial Results for Fourth Quarter, Full Year 2016 Mar 09 2017
Overview of MultiStem® Clinical Trial in Japan Presentation at International Stroke Conference 2017 Feb 23 2017
Athersys to Host Year-End 2016 Financial Results Call Feb 14 2017
Athersys Announces Closing of Public Offering of Common Stock Feb 01 2017
Athersys, Inc. (ATHX) Down, Maybe An Opportunity? Jan 31 2017
Athersys Launches $20M Public Stock Offering Jan 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)